News

4
Jan

Genoskin CSO obtains high-profile career award

GENOSKIN CSO OBTAINS HIGH-PROFILE CAREER AWARD To start the new year in good cheer, Genoskin is proud to announce that Dr. Nicolas Gaudenzio, our Chief Scientific Officer and Principal Investigator at Infinity, has recently obtained the Arloing-Courmont-Pasteur Institute career achievement award in human biology from the Academy of Science in Lyon, France. An award to highlight innovative scientific research The
Read more
6
Dec

PRESS RELEASE – Genoskin launches spatial skin biology platform MANTIS®

PRESS RELEASE - Toulouse, France & Salem, MA, USA - December 6, 2021 GENOSKIN LAUNCHES SPATIAL SKIN BIOLOGY PLATFORM MANTIS® Genoskin launches MANTIS®, a spatial biology imaging platform dedicated to skin immunology. The MANTIS® (Multiplex ANnotated Tissue Imaging System) platform was developed at Infinity (Inserm U1291, France) by a team of experts under the guidance of Dr. Nicolas Gaudenzio, who
Read more
8
Nov

PRESS RELEASE – Dr. Nicolas Gaudenzio is appointed Chief Scientific Officer at Genoskin

Genoskin appoints Dr Nicolas Gaudenzio as Chief Scientific Officer Today, November 8, Genoskin announces the appointment of Dr. Nicolas Gaudenzio as Chief Scientific Officer (CSO), starting in November. Dr. Gaudenzio will lead Genoskin's shift towards new activities Dr. Gaudenzio is a world-renowned researcher and expert in immunology and allergic skin inflammation. He is also principal investigator and leader of a
Read more
9
Jun

Interview with Pr. Guy Serre

10 Year Anniversary: Interview with Pr. Guy Serre For our 10th anniversary, we spoke to people who helped Genoskin become what it is today. Back in March, we had a chat with Pr. Guy Serre, Director of the UDEAR lab (Epidermis Differentiation and Rheumatoid Autoimmunity Unit), the place where Genoskin was born. Genoskin: Could you describe the relationship between your
Read more
28
Oct

A unique ex vivo perfused human skin model to test pharmacokinetic and systemic administration in human skin

The FlowSkin® platform : a unique ex vivo perfused human skin model to test pharmacokinetic and systemic administration in human skin When human tissue culture meets microfluidic technology, it leads to the first perfused human skin model ; an amazing platform to overcome the challenges of drug development and replace animal testing. Almost 10 years ago now, Genoskin developed the
Read more
7
Oct

Genoskin answers questions from National Anti-Vivisection Society

Genoskin interviewed by the National Anti-Vivisection Society on alternatives to animal testing Genoskin’s Chief Commercial Officer, Eric Merle, recently had the opportunity to speak with the National Anti-Vivisection Society (NAVS). Through a Q&A, Eric explains why Genoskin’s ex vivo human skin assays are a reliable alternative to animal testing. “We generate human data” Even though testing new drugs and compounds
Read more